1 result(s) displayed (1 - 1 of 1):
Amgen Inc. has deepened its presence in oncology -- a buzzing sector -- with an exclusive licensing deal with ImmunoGen Inc. (NASDAQ:IMGN), a developer of potential cancer therapies. Amgen will pay $1 million up-front and $34 million in potential milestone payments, plus royalties, to use ImmunoGen's technology to develop anticancer...
Posted on September 18, 2009 10:36 AM
Movable Type search results powered by Fast Search